{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-010149","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.939282+00:00","generated_at":"2026-05-24T21:14:04.797579+00:00","sec_items":["8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lipocine reports near-breakeven 2024; FDA requires Phase 3 for oral brexanolone","bullets":["Net income of ~$8,400 vs net loss of $16.4M in 2023; revenue of $11.2M from license/royalty fees.","Cash and securities $21.6M at Dec 31, 2024, vs $22.0M at Dec 31, 2023.","FDA meeting for LPCN 1154 requires safety/efficacy study for NDA; Phase 3 start expected Q2 2025.","TLANDO license agreements generated $10M in 2024; Verity milestones up to $259M plus tiered royalties.","FDA removed Boxed Warning on cardiovascular risk for testosterone products in Feb 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-010149","json":"https://secwatch.observer/filing/0001493152-25-010149.json","markdown":"https://secwatch.observer/filing/0001493152-25-010149.md","text":"https://secwatch.observer/filing/0001493152-25-010149.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315225010149/0001493152-25-010149-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315225010149/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T21:14:04.797579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}